{"id":990106,"date":"2026-08-05T07:51:17","date_gmt":"2026-08-05T11:51:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/"},"modified":"2026-08-05T07:51:17","modified_gmt":"2026-08-05T11:51:17","slug":"cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/","title":{"rendered":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Aug.  05, 2026  (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026.<\/p>\n<p>During the fireside chat, management will share recent progress in neflamapimod&#8217;s clinical development program.<\/p>\n<p>\n        <strong>Presentation Details<\/strong><br \/>\n        <br \/>Format: Fireside Chat<br \/>Date:\u00a0Tuesday, August 11, 2026<br \/>Time: 11:30 \u2013\u00a011:55 AM ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6gAQ4zWPBXT1teFg6tEC9A0OAwkpzt0cZ9gL1QnaMl3kNbYfnqKXQ6J3CchMS0fSXOiLOvWRlaYMeHTogdrTi1lp0TTLmbyILdDD0tBRwlqQvEufb7CzkNnoJ5jClRrN_SzVIBRFgISeinyZolouIMb_jCDWaiJNZQLy6nvrk3Kg5Hrvnt-_-Vnb3FRcch7GvXqxyMognuRbe9Ve-tWeJqzNR__tuu-_6oS-bgwGXNLwtNxeRzR3-BqtVYC2fktRujn4gARmJxCAGlJoa1e8-BRrKG1AD-I_hbyED_CiGQ23K-ifhrbcdfPfvham032e\" rel=\"nofollow\" target=\"_blank\">https:\/\/event.summitcast.com\/view\/WuFmFdTcA9mVsUGHZJFU62\/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ<\/a><\/p>\n<p>The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6gAQ4zWPBXT1teFg6tEC9F8Kp0sAQCtu6pUhYZ8vTDUdQnTU8AAly3C0s7gJxncy8pTPljlPkL1SUkWhjY0g4uI3R0CBMcaf1SE5aQFJI3apnv5KMoDI1hZrqoFS8leTYDaw1nFneSbf_mSOqQEAS3HAjttC5x2KZBYkDURH7_pnHEW1u0GkpritoqUcS973y9hL2t58BqnFFBLwq_T2Q4ISickuX8Pp2IVldzREeMoloRby6bGLJ0axXIY6Y_dsu04VS99uYb3Dpv-A6rMM0Q==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cervomed.com\/<\/a>.<\/p>\n<p>\n        <strong>About CervoMed<\/strong><br \/>\n        <br \/>CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed\u2019s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and\/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Lisa Guiterman<br \/>Biongage Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pI-hZdKyI9_mBqvqf_9olk3AnTDRIG5rnEbvvk_ohicFtD_0BPHCH0Ogz9Q4_oAjaJAjQkje2yNK4m4ZQ5-EYeJG8vszO_DAcuJLWg7pLUK3cheBoBFmz4WxEOIUa55u\" rel=\"nofollow\" target=\"_blank\">lisa.guiterman@gmail.com<\/a><br \/>202-330-3431<\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0nXQ7v5LzrTSjUn1rsiKJ33Q-rBBJjnU6mhxhVTyjwL9vXS6vARI8OUt1UKzKpRK4AIUPAwShpI4GsDgBqOdytxDl17PEewfujSQOaFPBK4odYe7Q1mXUy8NAIX5ku4L\" rel=\"nofollow\" target=\"_blank\">cervomed@argotpartners.com<\/a><br \/>212-600-1902\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmMyYWUxZTktZTkzZC00MGM3LWIyNmMtZjc4MDQ3MWY3Zjk3LTExOTYxMzktMjAyNi0wOC0wNS1lbg==\/tiny\/Cervomed.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod&#8217;s clinical development program. Presentation Details Format: Fireside ChatDate:\u00a0Tuesday, August 11, 2026Time: 11:30 \u2013\u00a011:55 AM ETWebcast Link: https:\/\/event.summitcast.com\/view\/WuFmFdTcA9mVsUGHZJFU62\/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website\u00a0https:\/\/www.cervomed.com\/. About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-990106","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod&#8217;s clinical development program. Presentation Details Format: Fireside ChatDate:\u00a0Tuesday, August 11, 2026Time: 11:30 \u2013\u00a011:55 AM ETWebcast Link: https:\/\/event.summitcast.com\/view\/WuFmFdTcA9mVsUGHZJFU62\/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website\u00a0https:\/\/www.cervomed.com\/. About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, &hellip; Continue reading &quot;CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T11:51:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference\",\"datePublished\":\"2026-08-05T11:51:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\"},\"wordCount\":314,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\",\"name\":\"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=\",\"datePublished\":\"2026-08-05T11:51:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk","og_description":"BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod&#8217;s clinical development program. Presentation Details Format: Fireside ChatDate:\u00a0Tuesday, August 11, 2026Time: 11:30 \u2013\u00a011:55 AM ETWebcast Link: https:\/\/event.summitcast.com\/view\/WuFmFdTcA9mVsUGHZJFU62\/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website\u00a0https:\/\/www.cervomed.com\/. About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, &hellip; Continue reading \"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-05T11:51:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference","datePublished":"2026-08-05T11:51:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/"},"wordCount":314,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/","name":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=","datePublished":"2026-08-05T11:51:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMzYwNyM3NzU4NzQ0IzIxODQ1ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-fireside-chat-to-highlight-recent-progress-in-the-neflamapimod-clinical-development-program-at-the-canaccord-genuity-46th-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=990106"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990106\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=990106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=990106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=990106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}